Eli Lilly's Retatrutide Shows 30% Weight Loss in Phase 3 Trial, Bolstering Obesity Pipeline
LLY sits 63% above its 52-week low of $623.78.
Summary
Eli Lilly's investigational weight-loss drug, retatrutide, achieved clinically meaningful weight loss in a Phase 3 trial, meeting its primary and key secondary endpoints. Participants on the highest dose lost an average of 30% of their body weight over two years. This strong data adds another powerful candidate to Lilly's leading obesity portfolio, which already includes Zepbound and the recently approved Foundayo. The results underscore Lilly's dominant position in the high-growth weight-loss market and its future revenue potential. More detailed trial results are expected to be shared later this year.
At the time of this announcement, LLY was trading at $1,017.35 on NYSE in the Life Sciences sector, with a market capitalization of approximately $959.5B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.